ArticleBMC cancer2026
Treatment patterns and clinical outcomes of metastatic gastric cancer in South Korea: real-world evidence from retrospective electronic medical records data.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundFive-year survival of patients with metastatic gastric cancer (mGC) is poor. Tumor characteristics, timing of diagnosis, and treatment patterns differ between patients from Eastern and Western regions. Therefore, we aimed to evaluate treatment patterns and outcomes of patients with mGC in South Korea.
methodsThis retrospective study aimed to analyze electronic medical records. Treatment patterns were evaluated in 2,229 patients, and clinical outcomes were assessed in 2,083 patients.
resultsThe median age of the included patients was 60 (range, 18–92) years (62.8%, male; 95.5% had Eastern Cooperative Oncology Group performance status score of 0–1). Among tested patients, HER2-positivity, microsatellite instability high/deficient mismatch repair (MSI-H/dMMR), and PD-L1 22C3 Combine Positive Score ≥ 1 rates were 16.0%, 4.7%, and 49.1%, respectively. Of the 2,353 patients, 94.7%, 68.0%, and 52.9% received first-line (1 L), second-line (2 L), third-line (3 L) therapy, respectively. Platinum doublets were used for 1 L (61.3%); paclitaxel plus ramucirumab, 2 L (50.6%); and, irinotecan-based therapy, 3 L (51.1%). The median overall survival (OS) was 3.8 and 16.3 months in the untreated and treated patients, respectively. Overall, HER2-positive patients treated with HER-2 targeted agent had a longer OS (19.1 months), and those treated with combined HER2-targeted plus immune checkpoint inhibitor (ICI) therapy (23.1 months) had the longest OS. In HER2-negative patients, OS was 15.7 months with chemotherapy, and 17.6 months with combined chemotherapy plus ICI. No survival differences were found between patients treated with oxaliplatin and cisplatin in 1 L, irinotecan and taxane in 2 L/3L, and across 2 L to 3 L sequences.
conclusionsA survival benefit was observed with multiple lines of therapy, particularly with immune checkpoint inhibitor (ICI) therapy, in both HER2-positive and HER2-negative patients. Our findings support the benefits of multiline personalized treatments in mGC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.